5 October 2016Americas

LSIPR 50 2016: Brook Byers and Beth Seidenberg

Names: Brook Byers and Beth Seidenberg

Organisation: Kleiner Perkins Caufield & Byers

Positions:  Founding member and general partner

Kleiner Perkins Caufield & Byers (KPCB) has invested in and helped build more than 100 life sciences companies that have developed products to treat underserved medical needs.

Brook Byers is the founding member of KPCB and president of four biotechnology companies that were developed in KPCB’s offices. All four went on to become public companies with an aggregate market value of more than $8 billion.

Beth Seidenberg is a general partner at KPCB and focuses on life sciences and investing in digital health and biotech companies. She works with entrepreneurs to develop companies with breakthrough technology for treating patients and improving the delivery of healthcare.

"She works with entrepreneurs to develop companies with breakthrough technology for treating patients."

Since joining KPCB in 2005, Seidenberg has helped nurture five companies.

One of them, Flexus Biosciences, which develops anti-cancer therapeutics, was bought by Bristol-Myers Squibb in 2015 in a deal worth $1.25 billion. In 2015, she was ranked number 91 in Forbes’ Midas List, which ranks the best deal makers in high-tech and life science venture capital spaces.